- About BIORISE
Dr Kleitos Sokratous worked as a postdoctoral researcher in Bioinformatics Group at The Cyprus Institute of Neurology and Genetics. His research interests liee in the areas of biomolecular mass spectrometry and omics as well as in the evolving field of computational modelling using mass spectrometry results. Mass spectrometry has evolved into a powerful analytical tool that can provide unique functional and structural information about protein–protein interactions, conformation, assembly and topology of biomolecular assemblies. Elucidation of structural and functional information of these assemblies would push forward the research for the development of novel therapeutic approaches.
He obtained his BSc in Chemistry from the University of Athens in 2005 and his MSc in Analytical and Pharmaceutical Science from Loughborough University, UK, in 2007. During his MSc studies, he took an industrial placement at 3M Health Care, Loughborough, where he performed a short research project under the supervision of Dr Helen Reid. In 2009, he joined the group of Dr. Neil Oldham at the University of Nottingham for his PhD studies in Chemistry, with particular focus on biomolecular mass spectrometry. His research project was focused on the investigation and quantification of the nature of ubiquitin-ubiquitin binding domain interactions by electrospray ionization mass spectrometry (ESI-MS). The project lead to the development and application of an ESI-MS based approach to probe affinity and selectivity of ubiquitin-binding. In addition, during his doctoral studies he has employed ion mobility–mass spectrometry (IM–MS) approaches and molecular dynamic simulations to investigate the effects of cation adducts upon the gas-phase conformational changes of small proteins. Furthermore, he has employed Fmoc-SPPS approach to synthesise a series of hexapeptides that mimic the C-terminal of ubiquitin, which could act as potential inhibitors of ubiquitin-ubiquitin binding domain interactionsthat involve the C-terminal region of ubiquitin.
After the completion of his doctoral studies, he moved to Cyprus and took a postdoc position at the “The Cyprus Institute of Neurology and Genetics. This position was part of a project that aimed in the establishment of the first MS-based proteomics facility. During this time, he took a leading role in the project and he worked closely with the head of the department and his collaborators on the appropriate selection of instruments and establishment of new protocols. After completion of the facility, he was responsible for the smooth operation of the facility, which is equipped with two MS instruments, a Synapt G2Si and a Xevo TQD, as well as two LC systems, a nanoAcquity UPLC and an Acquity I-Class UPLC. He has been involvedin multiple projects that aimed in the identification of novel biomarkers of Breast and Prostate cancer (Research Foundation Projects, Proteomics and Genomics of Breast and Prostate cancers). He currently participates in a European consortium that works towards the understanding of SLE (Systemic Lupus Erythematosus) genetics, proteomics and its translation to clinic (IMI funded project, PRECISESADS). In addition, he was involved in the supervision of two research projects (an MSc and a PhD) and he also delivers two lectures for a postgraduate course that is taking place at the Cyprus School of Molecular Medicine; MM102 (lecture entitled “The Human Proteome”).